2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Kenneth Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana–Farber Cancer Institute discusses combining immunotherapies in myeloma.
Kenneth Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana—Farber Cancer Institute discusses combining immunotherapies in myeloma.
Pairing lenalidomide and antibodies is just one example of the potential combinations that could be utilized in myeloma, says Anderson. Research is being conducted looking at checkpoint inhibitors used with vaccines as well as paired with lenalidomide or other similar drugs.
The ultimate goal of these combination treatments is to restore memory immune response in patients against their own tumor cells. If this could be achieved a cure is possible in myeloma, says Anderson.
Related Content: